SecBot SecBot
8-K ·Filed May 13, 2026

LITS

Lite Strategy, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001193125-26-220697
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor the next 10-Q filing for actual financial results and LTC holdings valuation. The lack of financial data in this press release is unusual and may indicate the company is prioritizing narrative over numbers.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
LITS ▼ -23.09% at T+60d
NEUTRAL call -23.09% · α vs SPY -27.53% · entry $1.18 → $0.9075
Entry = T+0 close
May 13, 2026
via day close
T+1d
+3.39%
call +3.39% · α +2.61%
$1.22
settled 6mo ago
T+5d
-7.63%
call -7.63% · α -6.47%
$1.09
settled 5mo ago
T+20d
-37.29%
call -37.29% · α -36.68%
$0.7400
settled 5mo ago
T+60d
-23.09%
call -23.09% · α -27.53%
$0.9075
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Lite Strategy, Inc. filed an 8-K with a press release for its fiscal Q3 2026 results ended March 31, 2026. The press release contains no revenue, EPS, or other financial statement data; it only describes operational highlights such as generating $0.7M in net proceeds from a covered call program and repurchasing 1,629,136 shares. Without any quantitative financial results, this filing is a routine operational update with no material impact on the stock.

Key Facts

  • Generated $0.7 million in net proceeds from covered call option program since October 2025.
  • Repurchased 1,629,136 shares using covered call proceeds and 35,250 LTC since October 2025.
  • SEC issued updated guidance in March 2026 indicating LTC exhibits characteristics of a digital commodity.
  • Company has a $25 million share repurchase authorization and plans to continue scaling its covered call program.
  • No financial statements (revenue, EPS, cash flow) were included in the press release.

Financial Impact

No financial data reported; only $0.7M in covered call proceeds and share repurchase activity disclosed.

Risk Factors

  • No financial data provided — inability to assess revenue, earnings, or cash flow trends.
  • Company's value is tied to volatile LTC price; impairment risk if LTC declines.
  • Pharmaceutical operations remain pre-clinical with no near-term revenue catalyst.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-220697
Document: lits-ex99_1.htm0001193125-26-220697
Document: 0001193125-26-220697-index-headers.html0001193125-26-220697
Document: 0001193125-26-220697-index.html0001193125-26-220697
Document: 0001193125-26-220697.txt0001193125-26-220697
8-K Data (Synthetic)0001193125-26-220697
6 reports for LITS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for LITS — sortable, filterable
TypeNow
Oct 7, 2026
20d ago
EFFECT
NEUTRAL ★ 3/10
$1.27awaiting T+60—$1.12 (−11.81%)
Sep 29, 2026
27d ago
Press Release
NEUTRAL ★ 5/10
$1.38awaiting T+60—$1.12 (−18.55%)
Jul 30, 2026
12w ago
8-K
BULLISH ★ 6/10
$0.9872 $1.16▲ +17.50%▲ +15.04%$1.12 (+13.45%)
Jul 24, 2026
13w ago
8-K
NEUTRAL ★ 3/10
$0.9765 $1.16▲ +18.79%▲ +15.09%$1.12 (+14.70%)
Jun 11, 2026
19w ago
Institutional Cluster
NEUTRAL ★ 2/10
$0.7398 $1.14▲ +54.10%▲ +49.70%$1.12 (+51.39%)
May 13, 2026
23w ago
8-K
NEUTRAL ★ 3/10
$1.18 $0.9075▼ −23.09%▼ −27.53%$1.12 (−5.08%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 1h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026